Results after Intraoperative Therapy in Malignant Pleural Mesothelioma
Pp. 469-478 (10)
Shamus R. Carr and Joseph S. Friedberg
Malignant pleural mesothelioma (MPM) is a virulent disease that is
essentially incurable. Although surgery cannot currently be considered standard of care,
there is general agreement that a certain subset of patients appear to benefit from
surgery-based multimodal treatments beyond what would be expected with the current
standard of care, pemetrexed-based chemotherapy alone. Exactly who those patients are
remains to be defined. One intuitively appealing aspect of surgery-based therapies is
that they allow for the employment of an intraoperative adjuvant therapy. There are
multiple intraoperative adjuvant therapies, each with their own advantages and
disadvantages. This chapter is a review of these treatments.
Intraoperative therapy, intrapleural chemotherapy, outcomes,
University of Maryland School of Medicine, Division of Thoracic Surgery, 29 Greene St, Suite 504, 21201 Baltimore, MD, United States.